Owlet Inc (OWLT) — Titan Protect Analysis

OWLT

Owlet Inc

Healthcare · ·

$4.67

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$146M

Total market value of the company

Trailing P/E

N/A

Forward P/E

45.77

Based on estimated future earnings — lower means cheaper

Rev Growth

+6.4%

Year-over-year revenue change

Profit Margin

-43.0%

How much profit the company keeps from each dollar of revenue

ROE

-526.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$13.50

+189% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Owlet Inc

Owlet, Inc. provides digital parenting solutions in the United States, the United Kingdom, and internationally. The company offers a digital parenting platform that provides real-time data and insights to parents. It also provides sock monitors, including Dream Sock, a wearable infant health monitor equipped with pulse oximetry technology that tracks vital signs, such as pulse rate, activity, oxygen level, and sleep patterns; BabySat, which is intended for infants with conditions, including resp

https://www.owletcare.com

Country: United States Employees: 108 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.448

Positive but modest risk-adjusted returns

Kelly Fraction

0.0141

Marginal edge — very small allocation suggested

Calmar Ratio

0.044

Drawdown risk outweighs the returns — higher risk profile

Annual Return

3.2%

Historical annualised return based on price data

Max Drawdown

-72.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.84

Significantly more volatile than the market

52W High

$16.94

72% below the year high

52W Low

$4.19

11% above the year low

Avg Volume

329,703

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.57

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

55.44

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

50.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-24.5%

Profit from core operations before interest and tax

Free Cash Flow

$-10,622,500

Negative — the business is spending more than it generates

Revenue (TTM)

$107M

Total revenue over the last 12 months

Net Income

$-47,745,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$15.00

Target Median

$13.50

Target Low

$13.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go